- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04982393
BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1) (BONAPH1DE)
May 9, 2024 updated by: Alnylam Pharmaceuticals
The purpose of this study is to describe the natural history and progression of patients diagnosed with PH1, and to characterize the long-term real-world safety and effectiveness of lumasiran.
Study Overview
Status
Recruiting
Conditions
Study Type
Observational
Enrollment (Estimated)
200
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Alnylam Clinical Trial Information Line
- Phone Number: 1-877-ALNYLAM
- Email: clinicaltrials@alnylam.com
Study Contact Backup
- Name: Alnylam Clinical Trial Information Line
- Phone Number: 1-877-256-9526
- Email: clinicaltrials@alnylam.com
Study Locations
-
-
-
Gent, Belgium
- Recruiting
- Clinical Trial Site
-
Liège, Belgium
- Recruiting
- Clinical Trial Site
-
-
-
-
Ontario
-
Hamilton, Ontario, Canada
- Recruiting
- Clinical Trial Site
-
Toronto, Ontario, Canada
- Not yet recruiting
- Clinical Trial Site
-
-
Quebec
-
Laurier, Quebec, Canada
- Recruiting
- Clinical Trial Site
-
-
-
-
-
Bordeaux, France
- Recruiting
- Clinical Trial Site
-
Lyon, France
- Recruiting
- Clinical Trial Site
-
Paris, France
- Recruiting
- Clinical Trial Site
-
-
-
-
-
Berlin, Germany
- Recruiting
- Clinical Trial Site
-
Cologne, Germany
- Recruiting
- Clinical Trial Site
-
Hamburg, Germany
- Recruiting
- Clinical Trial Site
-
-
-
-
-
Jerusalem, Israel
- Recruiting
- Clinical Trial Site
-
-
-
-
Torino
-
Orbassano, Torino, Italy
- Recruiting
- Clinical Trial Site
-
-
-
-
-
Barcelona, Spain
- Recruiting
- Clinical Trial Site
-
-
-
-
-
Bern, Switzerland
- Recruiting
- Clinical Trial Site
-
-
-
-
England
-
London, England, United Kingdom
- Recruiting
- Clinical Trial Site
-
-
-
-
Arizona
-
Phoenix, Arizona, United States, 85016
- Recruiting
- Clinical Trial Site
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010
- Recruiting
- Clinical Trial Site
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Recruiting
- Clinical Trial Site
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Recruiting
- Clinical Trial Site
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229
- Recruiting
- Clinical Trial Site
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- Recruiting
- Clinical Trial Site
-
-
Texas
-
Dallas, Texas, United States, 75390
- Recruiting
- Clinical Trial Site
-
Houston, Texas, United States, 77030
- Recruiting
- Clinical Trial Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Patients diagnosed with PH1 will be managed and treated per routine clinical practice.
Description
Inclusion Criteria:
- Documented diagnosis of PH1, per physician's determination
Exclusion Criteria:
- Currently enrolled in a clinical trial for any investigational agent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
Patients with PH1
Patients with a diagnosis of PH1 will be eligible for the study and will be managed and treated per routine clinical practice.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of Adverse Events in Lumasiran Treated Patients
Time Frame: Up to 7 years
|
Up to 7 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Selected Events of Interest in PH1 Patients
Time Frame: Up to 7 years
|
Selected events of interest are defined as hepatic events, kidney stones, acute kidney injury events, nephrocalcinosis, chromic kidney disease, kidney failure, and any cardiac, bone, skin, eye, hematological, or neuropathic manifestations due to oxalosis.
|
Up to 7 years
|
12-Item Short Form Health Survey Version 2 (SF-12 V2) (Standard Version)
Time Frame: Up to 7 years
|
SF-12 V2 is a 12-question measure capturing global quality of life and overall health status and evaluates the following 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health.
|
Up to 7 years
|
Change in Urinary Oxalate Excretion
Time Frame: Baseline and every 12 months for up to 7 years
|
Baseline and every 12 months for up to 7 years
|
|
Change in Plasma Oxalate
Time Frame: Baseline and every 12 months for up to 7 years
|
Baseline and every 12 months for up to 7 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Medical Director, Alnylam Pharmaceuticals
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 13, 2021
Primary Completion (Estimated)
September 1, 2028
Study Completion (Estimated)
September 1, 2028
Study Registration Dates
First Submitted
July 20, 2021
First Submitted That Met QC Criteria
July 20, 2021
First Posted (Actual)
July 29, 2021
Study Record Updates
Last Update Posted (Actual)
May 10, 2024
Last Update Submitted That Met QC Criteria
May 9, 2024
Last Verified
May 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Metabolic Diseases
- Kidney Diseases
- Urologic Diseases
- Genetic Diseases, Inborn
- Carbohydrate Metabolism, Inborn Errors
- Metabolism, Inborn Errors
- Hyperoxaluria
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Hyperoxaluria, Primary
Other Study ID Numbers
- ALN-GO1-007
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Primary Hyperoxaluria Type 1
-
Dicerna Pharmaceuticals, Inc.CompletedKidney Diseases | Urologic Diseases | Genetic Disease | Primary Hyperoxaluria Type 1 (PH1) | Primary Hyperoxaluria Type 2 (PH2)Poland, United Kingdom, New Zealand, United States, Australia, Canada, France, Germany, Israel, Italy, Japan, Lebanon, Netherlands, Romania, Spain
-
Alnylam PharmaceuticalsCompletedPrimary Hyperoxaluria Type 1 (PH1)France, United Kingdom, Netherlands, Israel, Germany
-
Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyEnrolling by invitationKidney Diseases | Urologic Diseases | Genetic Disease | Primary Hyperoxaluria Type 1 (PH1) | Primary Hyperoxaluria Type 2 (PH2) | Primary Hyperoxaluria Type 3 (PH3)United States, France, Germany, Japan, Lebanon, Spain, United Kingdom, Australia, Canada, Italy, Netherlands, Norway, Turkey
-
Alnylam PharmaceuticalsActive, not recruitingPrimary Hyperoxaluria Type 1 (PH1) | Primary HyperoxaluriaUnited States, France, United Kingdom, Israel, Germany
-
Alnylam PharmaceuticalsCompletedPrimary Hyperoxaluria Type 1 (PH1)United States, France, United Kingdom, Switzerland, Netherlands, Israel, Germany, United Arab Emirates
-
Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyAvailablePrimary Hyperoxaluria Type 1 (PH1)
-
Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyRecruitingPrimary Hyperoxaluria Type 3 | Primary Hyperoxaluria Type 2 | Primary Hyperoxaluria Type 1 | Primary HyperoxaluriaUnited States, Canada, Lebanon, Turkey, United Kingdom, Germany, Italy, Japan, Poland, Spain, United Arab Emirates
-
Dicerna Pharmaceuticals, Inc.TerminatedPrimary Hyperoxaluria Type 1Netherlands, Germany
-
Ann & Robert H Lurie Children's Hospital of ChicagoMayo Clinic; National Institute of Diabetes and Digestive and Kidney Diseases...CompletedPrimary Hyperoxaluria Type 1
-
Hospices Civils de LyonCompletedIdiopathic Hypercalciuria | Primary Hyperoxaluria Type 1France